Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2021 Nov 1;19(1):19.
doi: 10.1186/s12948-021-00159-4.

The potential protective role of corticosteroid therapy in patients with asthma and COPD against COVID-19

Fabiana Furci  1 , Marco Caminati  2 , Gianenrico Senna  2   3 , Sebastiano Gangemi  4
Affiliations
Review

The potential protective role of corticosteroid therapy in patients with asthma and COPD against COVID-19

Fabiana Furci et al. Clin Mol Allergy. .

Abstract

Background: The observation of patients hospitalized for coronavirus disease (COVID-19) led us to note a lower prevalence of patients affected by chronic respiratory disease, in particular asthmatic patients, compared to the general population. Therefore, the aim of this paper is to evaluate the possible protective role of corticosteroid therapy in patients with chronic lung disease, regarding the risk of contracting severe COVID-19.

Main body: SARS-CoV-2 uses angiotensin-converting enzyme 2 (ACE2) receptors to enter the cells. Considering the high number of these receptors in patients affected by asthma and chronic obstructive pulmonary disease (COPD), the evidence that these patients do not have a high risk of hospitalization for COVID-19 needs further study to understand what the possible protective "factors" are in these patients. In particular, the finding in some studies of reduced coronavirus replication in cell lines treated with steroids, molecules commonly used for treating chronic lung diseases, needs further attention.

Short conclusion: The hypothesis that corticosteroids, commonly used in treating airways diseases, might modify the severity of SARS-CoV-2 disease has become a key point and a possible predictive factor of a positive outcome of COVID-19 in patients treated everyday with these molecules.

Keywords: Asthma; COPD; COVID-19; Corticosteroids; Hospitalization; Pulmonary diseases.

PubMed Disclaimer

Conflict of interest statement

The authors declare that they do not have any conflict of interest.

References

    1. Rogliani P, Lauro D, Di Daniele N, Chetta A, Calzetta L. Reduced risk of COVID-19 hospitalization in asthmatic and COPD patients: a benefit of inhaled corticosteroids? Expert Rev Respir Med. 2021;15:561–568. doi: 10.1080/17476348.2021.1850275. - DOI - PMC - PubMed
    1. Li X, Xu S, Yu M, Wang K, Tao Y, Zhou Y, et al. Risk factors for severity and mortality in adult COVID-19 in patients in Wuhan. J Allergy Clin Immunol. 2020;146:110–118. doi: 10.1016/j.jaci.2020.04.006. - DOI - PMC - PubMed
    1. Caminati M, Lombardi C, Micheletto C, Roca E, Bigni B, Furci F, et al. Asthmatic patients in COVID-19 outbreak: few cases despite many cases. J Allergy Clin Immunol. 2020;146:541–542. doi: 10.1016/j.jaci.2020.05.049. - DOI - PMC - PubMed
    1. Jeon S, Ko M, Lee J. Identification of antiviral drug candidates against SARS-CoV-2 from FDA-approved drugs. Antimicrob Agents Chemother. 2020;64:00819–00820. doi: 10.1128/AAC.00819-20. - DOI - PMC - PubMed
    1. Yamaya M, Nishimura H, Deng X. Inhibitory effects of glycopyrronium, formoterol, and budesonide on coronavirus HCoV-229E replication and cytokine production by primary cultures of human nasal and tracheal epithelial cells. Respir Investig. 2020;58:155–168. doi: 10.1016/j.resinv.2019.12.005. - DOI - PMC - PubMed

Grants and funding

LinkOut - more resources